ArticleCureus2025
Correlation of NT-proBNP With Duration of Hospital Stay in Patients With Heart Failure: A Retrospective Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeart failure (HF) is a leading cause of hospitalization and mortality worldwide, and the burden of the disease is increasing on a daily basis. N-terminal pro-B-type natriuretic peptide (NT-proBNP) is an established biomarker for diagnosis and prognosis in HF, but its relationship with length of hospital stay remains underexplored. Understanding this association may help in early risk stratification and optimize healthcare resource utilization.
objectiveTo evaluate the correlation between NT-proBNP levels and length of hospital stay in patients admitted with HF and to identify clinical predictors of in-hospital mortality.
methodsThis retrospective observational study included 45 patients admitted with HF to Father Muller Medical College Hospital, Mangalore, between October 2024 and May 2025. Demographic, clinical, echocardiographic, and laboratory data, including NT-proBNP levels, were collected from hospital records. Statistical analyses were performed using Jamovi 2.7 and R Studio. Correlations were assessed using Spearman's rank test, and predictors of in-hospital mortality were evaluated with univariate Firth logistic regression and ROC analysis.
resultsThe mean age of participants was 64.8 ± 10.5 years; 53.3% were female. The mean NT-proBNP level was 6443 ± 4953 pg/mL, and the mean hospital stay was 10.8 ± 6.4 days. NT-proBNP levels were significantly higher in non-survivors (10977 ± 5687 pg/mL) than survivors (5607 ± 4396 pg/mL; p = 0.027). A moderate positive correlation was observed between NT-proBNP and hospital stay (ρ = 0.425, p = 0.004). ROC analysis identified an NT-proBNP cut-off of 8823 pg/mL for predicting mortality (AUC = 0.76, sensitivity = 86%, specificity = 79%).
conclusionElevated NT-proBNP levels at admission are strongly associated with prolonged hospital stay and increased in-hospital mortality among HF patients. NT-proBNP may serve as a valuable biomarker for early risk stratification and assessing prognosis, enabling efficient resource allocation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.